Influence of parathyroid mass on the regulation of PTH secretion

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky 
E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P
Volume 60, Issue 6, Pages (December 2001)
Volume 90, Issue 1, Pages (July 2016)
Volume 70, Issue 3, Pages (August 2006)
Volume 88, Issue 6, Pages (December 2015)
Volume 90, Issue 1, Pages (July 2016)
FGF23–parathyroid interaction: implications in chronic kidney disease
Volume 72, Issue 1, Pages (July 2007)
Volume 92, Issue 1, Pages (July 2017)
Volume 70, Issue 3, Pages (August 2006)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats  Eduardo Slatopolsky, Mario Cozzolino,
Response to is the reduction in urea distribution volume over time in clinically stable dialysis patients real?  S. Andrulli, S. Di Filippo, F. Locatelli 
Volume 60, Issue 6, Pages (December 2001)
Volume 70, Pages S21-S25 (December 2006)
Volume 70, Pages S12-S15 (July 2006)
George A. Kaysen, Burl R. Don
Tally Naveh-Many, Justin Silver  Kidney International 
Circulating PTH molecular forms: What we know and what we don't
D. Batlle, P. Ramadugu, M.J. Soler  Kidney International 
Volume 70, Issue 11, Pages (December 2006)
Volume 79, Pages S20-S23 (April 2011)
The need for reliable serum parathyroid hormone measurements
D. Coyne  Kidney International  Volume 69, Pages S1-S3 (May 2006)
Volume 67, Pages S33-S36 (June 2005)
Ewa Lewin, Yolanda Almaden, Mariano Rodriguez, Klaus Olgaard 
Volume 73, Pages S5-S17 (April 2008)
Acute myocardial infarction in patients with end-stage renal disease
Volume 69, Issue 3, Pages (February 2006)
Relationship between methylmalonic acid and cobalamin in uremia
Blood pressure targets in hemodialysis patients
Volume 68, Pages S24-S28 (July 2005)
The third World Kidney Day: Looking back and thinking forward
M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky 
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Volume 87, Issue 3, Pages (March 2015)
Volume 59, Issue 3, Pages (March 2001)
Pathogenic mechanisms for parathyroid hyperplasia
AGEs in foods: Do they play a role in uremia?
Volume 85, Issue 1, Pages 3-4 (January 2014)
Increased workload fully activates the blunted IRS-1/PI3-kinase/Akt signaling pathway in atrophied uremic muscle  Y. Chen, S. Sood, J. Biada, R. Roth,
Pathogenesis of refractory secondary hyperparathyroidism
What can be learned using microarrays?
Neurogenic factors and hypertension in renal disease
Volume 79, Issue 7, Pages (April 2011)
Volume 75, Issue 9, Pages (May 2009)
Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics  William G. Goodman, L.D. Quarles 
Fibroblast growth factor 23: the making of a hormone
Leptin and inflammation-associated cachexia in chronic kidney disease
Organ transplantation goes to the movies
Volume 70, Pages S84-S90 (November 2006)
Pablo A. Ureña Torres, Marc De Broe  Kidney International 
Increased parathyroid expression of klotho in uremic rats
Volume 70, Issue 3, Pages (August 2006)
Volume 66, Issue 6, Pages (December 2004)
Volume 71, Issue 9, Pages (May 2007)
Volume 64, Issue 1, Pages (July 2003)
Volume 70, Issue 5, Pages (September 2006)
The International Pediatric Peritonitis Registry: Starting to walk
The ins and outs of phosphate homeostasis
Tumor necrosis factor-α in cisplatin nephrotoxicity: A homebred foe?
Volume 60, Issue 5, Pages (November 2001)
Control of uremic bone disease: Role of vitamin D analogs
Volume 61, Issue 4, Pages (April 2002)
Volume 55, Issue 5, Pages (May 1999)
A novel mechanism for skeletal resistance in uremia
Volume 64, Pages S131-S136 (November 2003)
Presentation transcript:

Influence of parathyroid mass on the regulation of PTH secretion E. Lewin, K. Olgaard  Kidney International  Volume 70, Pages S16-S21 (July 2006) DOI: 10.1038/sj.ki.5001597 Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 1 Expression of autocrine/paracrine factors might modulate parathyroid function. (a–b) Enhanced expression of PTHrP has been demonstrated in glands from patients with severe sec. HPT due to uremia. PTH/PTHrP receptor was demonstrated in the parathyroids. This figure shows the effect of N-terminal PTHrP on the secretory response of PTH to an acute induction of hypocalcemia in the rat. The rate of reduction of plasma-Ca2+ by an ethyleneglycol-bis(β-aminoethyl ether) N,N,N′,N′-tetraacetic acid (EGTA) infusion was similar in all groups of rats. A bolus of PTHrP 1–40, PTHrP 1–86, or vehicle was injected at time 0. PTHrP significantly enhanced by 300% (P<0.001) the low-Ca2+-stimulated PTH secretion in vivo. N=6 in each group, mean±s.e.m. Modified from Lewin et al.58 Kidney International 2006 70, S16-S21DOI: (10.1038/sj.ki.5001597) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 2 Even considerable parathyroid hyperplasia can be controlled in the normal organism. When 20 isogenic parathyroid glands were implanted into one PTX rat a short-lasting hypercalcemia was induced, soon followed, however, by normalization of Ca2+ and PTH levels. This figure shows plasma Ca2+ and plasma PTH levels in rats with 20 isogenic parathyroid glands implanted. Parathyroidectomy of their own parathyroid glands was performed on day 0, before the implantation of the 20 glands. The line (—) depicts plasma Ca2+ levels, while the bars depict PTH levels. N=6, mean±s.e.m. *P<0.05 versus the level at day 0, before PTX. Modified from Lewin et al.27 Kidney International 2006 70, S16-S21DOI: (10.1038/sj.ki.5001597) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 3 Severe parathyroid hyperplasia can be controlled when the functional demand for increased PTH levels is abolished by normalization of the kidney function. This figure shows kidney function and basal PTH levels before introduction of uremia by 5/6 nephrectomy (-20 weeks), during uremia (-20 to 0 weeks), and after reversal of uremia by an isogenic kidney transplantation (TX). The lines (—) depict kidney function expressed as plasma urea and the bars depict PTH levels. The uremic rats were kept on a high P diet. N=12, mean±s.e.m. Modified from Lewin et al.27 Kidney International 2006 70, S16-S21DOI: (10.1038/sj.ki.5001597) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 4 Suppressibility of PTH secretion by Ca2+ is not influenced by the parathyroid mass, itself. Parathyroid function was investigated by the Ca2+/PTH relationship during acute inductions of hypocalcemia and hypercalcemia in uremic rats kept on high P diet (Uremia-P), kidney transplanted, 3 weeks after transplantation (TX), and in normal control rats (controls). The PTH secretory response to hypocalcemia was significantly higher in uremic rats (P<0.001) than in kidney transplanted and normal control rats. The PTH secretion was suppressed to same extend in kidney transplanted rats and normal control rats, while uremic hyperphosphatemic rats had a significantly higher (P<0.05) PTH secretion at high Ca2+. N=6, mean±s.e.m. Modified from Lewin et al.27 Kidney International 2006 70, S16-S21DOI: (10.1038/sj.ki.5001597) Copyright © 2006 International Society of Nephrology Terms and Conditions

Figure 5 Upregulation of the parathyroid CaR gene expression after reversal of uremia by kidney transplantation (TX) does not occur immediately. The expression of CaR was still diminished 1 week after TX, at a time when circulating PTH levels already were normalized. The figure shows the CaR gene expression in the parathyroid glands of normal control rats, uremic rats on a high P diet (CRF hP), and kidney transplanted (TX), 1 and 4 weeks after kidney transplantation. N=5–8, mean±s.e.m. *P<0.001 versus control rats. Kidney International 2006 70, S16-S21DOI: (10.1038/sj.ki.5001597) Copyright © 2006 International Society of Nephrology Terms and Conditions